BioPharma Dive

MARCH 25, 2024

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Immunity 65

Immunity Immunization Drug Development 65

STAT

OCTOBER 29, 2024

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Cancer vaccines may also be able to help train the immune system to recognize and kill cancers related to viruses like HPV.

Vaccines 360

Vaccines Immunity Immunization Drug Development 360

Outsourcing Pharma

DECEMBER 21, 2020

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

Immunity 94

Immunity Immunization Drug Development 94

BioPharma Dive

JUNE 20, 2023

The deal adds to recent M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.

Immunity 95

Immunity Immunization Drug Development 95

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drug development forum.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

JUNE 15, 2022

The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. Improve your drug development rationale across all lines of NSCLC and address challenges when moving therapies forward. Progress sequencing and combination approaches.

Drug Development 104

Drug Development Immunity Immunization 104

World Pharma News

MAY 23, 2023

Jude Children’s Research Hospital and the University of Texas Southwestern Medical Center studied the structure and function of a transporter involved in cancer and immunity. The findings, published in Cell, have implications for drug development.

Drug Development 80

Drug Development Immunization Immunity Hospitals 80

STAT

MAY 22, 2024

Startlingly effective shots quickly helped immunize a large portion of the population — at least initially, and in high-income countries. During the Covid-19 pandemic, vaccines were the main line of defense. Antiviral treatments were not as impactful.

Vaccines 322

Vaccines Immunity Immunization Drug Development 322

BioPharma Dive

AUGUST 22, 2023

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Immunity 98

Immunity Immunization Drug Development 98

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Drug Development 123

Drug Development Immunity Immunization Vaccines 123

STAT

MARCH 28, 2024

Today, we’re reading about the world’s costliest drug, plus we learn about immune senescence and a potential cause for a kidney autoimmune disease. Sign up to get it in your inbox here. It’s Meghana. Read the rest…

Immunity 248

Immunity Immunization Drug Pricing Drug Development 248

BioPharma Dive

OCTOBER 31, 2024

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.

Immunization 61

Immunization Immunity Drug Development 61

STAT

APRIL 10, 2024

The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.

Vaccines 363

Vaccines Immunity Immunization Drug Development 363

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunization 65

Immunization Immunity Drug Development 65

STAT

NOVEMBER 28, 2023

The negative study, called ADVANCE-SC, was the second of two clinical trials involving the Argenx drug called efgartigimod in patients with primary immune thrombocytopenia (ITP), a debilitating condition that destroys blood-clotting platelets. Argenx shares were down 12% in early trading.

Immunity 262

Immunity Immunization Drug Development 262

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunization 61

Immunization Immunity Drug Development 61

BioPharma Dive

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development 57

Drug Development Immunization Immunity 57

STAT

SEPTEMBER 26, 2023

Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.

Immunity 322

Immunity Immunization Drug Development 322

STAT

DECEMBER 22, 2022

Sepsis, a deadly overreaction of the immune system to infection, has befuddled clinicians and researchers for decades. Covid-19 made things worse.

Immunity 323

Immunity Immunization Drug Development 323

STAT

MAY 16, 2024

The need-to-know this morning Biogen  and  Ionis Pharmaceuticals  are  ending their development  of an experimental drug for ALS based on results of a Phase 1/2 trial. Novartis  said it’s  met all tender offer conditions  to acquire German biotech Morphosys.

Immunity 246

Immunity Immunization Drug Pricing Drug Development 246

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunity Immunization 98

European Pharmaceutical Review

MAY 14, 2024

Takeda and AC Immune SA have agreed a global option and license agreement for a potential first-in-class Abeta-targeting active immunotherapy for Alzheimer’s. AC Immune’s related immunotherapies targeting Abeta are part of the deal, including the Alzheimer’s treatment ACI-24.060.

Immunization 97

Immunization Immunity Drug Development 97

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Register for your FREE ticket here: [link].

Drug Development 52

Drug Development Immunity Immunization 52

pharmaphorum

MARCH 10, 2022

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms. The post Welcome to the 2nd Chronic HBV Drug Development Summit appeared first on.

Drug Development 52

Drug Development Immunity Immunization Vaccines 52

Pharmaceutical Technology

APRIL 5, 2023

Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development. Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses.

Drug Development 52

Drug Development Immunity Immunization 52

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immunization 111

Immunization Immunity Drug Development 111

STAT

OCTOBER 24, 2024

Among the basic and life-saving medicines for which shortages continue to be problematic are Rho(D) immune globulin, pain and sedation medications, and ADHD pills. So far this year, 95 new shortages were reported, a drop from 156 in 2023, although 50% of active shortages have persisted for two or more years.

Immunity 250

Immunity Immunization Drug Pricing Drug Development 250

pharmaphorum

APRIL 20, 2021

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. The post Non-Small Cell Lung Cancer Drug Development Summit appeared first on. View the event guide now for more details!

Drug Development 52

Drug Development Medical Schools Immunity Immunization 52

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. It also bodes well for improving clinical trial success rates.

Immunity 133

Immunity Immunization Drug Development 133

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunity 100

Immunity Immunization Drug Development 100

pharmaphorum

APRIL 12, 2021

This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunization 52

Immunization Immunity Drug Development 52

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Immunity 97

Immunity Immunization Hospitals Drug Development 97

pharmaphorum

OCTOBER 6, 2022

As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissues form the tumour micro-environment (TME).

Immunization 52

Immunization Immunity Drug Development 52

European Pharmaceutical Review

AUGUST 9, 2023

As a highly selective BTK inhibitor, remibrutinib “has the potential to be a first-in-class, oral treatment for people living with CSU whose symptoms are refractory despite use of antihistamines,” stated Dr Shreeram Aradhye, President of Global Drug Development and Chief Medical Officer at Novartis.

Immunity 94

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 94

pharmaphorum

NOVEMBER 11, 2022

Pick the brains of 140+ senior level drug developers across industry and academia at the physical return of the only meeting dedicated to overcoming challenges in biomarker understanding, disease selection and clinical translation in inflammasome-centered drug development.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

Drug Development 52

Drug Development Immunity Immunization Hospitals 52